Publicacions
-
Gimenez, N, Schulz, R, Higashi, M, Aymerich, M, Villamor, N, Delgado, J, Juan-Otero M, Lopez-Guerra, M, Campo, E, Rosich, L, Seiffert, M and Colomer, D.
Targeting IRAK4 disrupts inflammatory pathways and delays tumor development in chronic lymphocytic leukemia
Leukemia . 34(1): 100-114. Nº de cites: 29
-
Egri N, de Landazuri IO, Bartolomé CS, Ortega JR, Español-Rego M and Juan-Otero M.
CART manufacturing process and reasons for academy-pharma collaboration
IMMUNOLOGY LETTERS . 217: 39-48. Nº de cites: 7
-
Zanetti SR, Romecin PA, Vinyoles M, Juan-Otero M, Fuster JL, Camós-Guijosa M, Querol S, Delgado M and Menendez P.
Bone marrow MSC from pediatric patients with B-ALL highly immunosuppress T-cell responses but do not compromise CD19-CAR T-cell activity
Journal for ImmunoTherapy of Cancer . 8(2): . Nº de cites: 15
-
Jiménez-Feijoo R, Pascal M, Moya R, Riggioni C, Domínguez-Sánchez O, Lózano J, Álvaro-Lozano M, Piquert M, Machinena A, Folque M, Dias-Da Costa M, Carnés J and Plaza-Martín AM.
Molecular Diagnosis in House Dust Mite-Allergic Patients Suggests That Der p 23 Is Clinically Relevant in Asthmatic Children
JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY . 30(2): 127-132. Nº de cites: 27
-
Herrera L, Santos S, Vesga MA, Anguita J, Martin-Ruiz I, Carrascosa T, Juan-Otero M and Eguizabal C.
Adult peripheral blood and umbilical cord blood NK cells are good sources for effective CAR therapy against CD19 positive leukemic cells
SCIENTIFIC REPORTS . 9: 18729-18729. Nº de cites: 74
-
Foeldvari I, Klotsche J, Simonini G, Edelsten C, Angeles-Han ST, Bangsgaard R, de Boer J, Brumm G, Torrent RB, Constantin T, DeLibero C, Diaz J, Gerloni VM, Guedes M, Heiligenhaus A, Kotaniemi K, Leinonen S, Minden K, Miranda V, Miserocchi E, Nielsen S, Niewerth M, Pontikaki I, García de Vicuña-Muñoz C, Zilhao C, Yeh S, Anton-Lopez J and Calzada-Hernández J.
Proposal for a definition for response to treatment, inactive disease and damage for JIA associated uveitis based on the validation of a uveitis related JIA outcome measures from the Multinational Interdisciplinary Working Group for Uveitis in Childhood (MIWGUC)
PEDIATRIC RHEUMATOLOGY . 17(1): 66-66. Nº de cites: 27
-
Gattorno M, Hofer M, Federici S, Vanoni F, Bovis F, Aksentijevich I, Anton-Lopez J, Arostegui-Gorospe JI, Barron K, Ben-Cherit E, Brogan PA, Cantarini L, Ceccherini I, De Benedetti F, Dedeoglu F, Demirkaya E, Frenkel J, Goldbach-Mansky R, Gul A, Hentgen V, Hoffman H, Kallinich T, Kone-Paut I, Kuemmerle-Deschner J, Lachmann HJ, Laxer RM, Livneh A, Obici L, Ozen S, Rowczenio D, Russo R, Shinar Y, Simon A, Toplak N, Touitou I, Uziel Y, van Gijn M, Foell D, Garassino C, Kastner D, Martini A, Sormani MP and Ruperto N.
Classification criteria for autoinflammatory recurrent fevers.
ANNALS OF THE RHEUMATIC DISEASES . 78(8): 1025-1032. Nº de cites: 219
-
Zulian F, Culpo R, Sperotto F, Anton-Lopez J, Avcin T, Baildam EM, Boros C, Chaitow J, Constantin T, Kasapcopur O, Knupp Feitosa de Oliveira S, Pilkington CA, Russo R, Toplak N, van Royen A, Saad Magalhães C, Vastert SJ, Wulffraat NM and Foeldvari I.
Consensus-based recommendations for the management of juvenile localised scleroderma
ANNALS OF THE RHEUMATIC DISEASES . 78(8): 1019-1024. Nº de cites: 69
-
Mastrangelo G, Foeldvari I, Anton-Lopez J and Simonini G.
Defining outcome measures in juvenile idiopathic arthritis associated uveitis by a systematic review analysis: do we need a consensus?
PEDIATRIC RHEUMATOLOGY . 17: 40-40. Nº de cites: 8
-
Folqué-Giménez MM, Lozano-Blasco J, Riggioni C, Piquer-Gibert M, Alvaro-Lozano M, Machinena A, Giner MT, Domínguez-Sánchez O, Jiménez-Feijoo R, Dias-Da Costa M and Plaza-Martín AM.
'Real-life' experience in asthmatic children treated with omalizumab up to six-years follow-up
ALLERGOLOGIA ET IMMUNOPATHOLOGIA . 47(4): 336-341. Nº de cites: 10